Sotera Health Past Earnings Performance
Past criteria checks 2/6
Sotera Health's earnings have been declining at an average annual rate of -9.8%, while the Life Sciences industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 7.8% per year. Sotera Health's return on equity is 15%, and it has net margins of 6.3%.
Key information
-9.8%
Earnings growth rate
-8.4%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 7.8% |
| Return on equity | 15.0% |
| Net Margin | 6.3% |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
Why Sotera Health Company (NASDAQ:SHC) Could Be Worth Watching
Jan 06
Here's Why Sotera Health (NASDAQ:SHC) Has A Meaningful Debt Burden
Dec 05Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable
Sep 02Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt
Jun 25Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 30The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%
Mar 21Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models
Mar 01McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount
Feb 08Is Sotera Health (NASDAQ:SHC) A Risky Investment?
Feb 06Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump
Dec 28Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price
Dec 11An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued
Sep 10Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jun 05Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?
Feb 13Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher
Nov 24Revenue & Expenses Breakdown
How Sotera Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,120 | 70 | 175 | 0 |
| 30 Jun 24 | 1,098 | 40 | 167 | 0 |
| 31 Mar 24 | 1,077 | 55 | 163 | 0 |
| 31 Dec 23 | 1,049 | 51 | 160 | 0 |
| 30 Sep 23 | 991 | -306 | 180 | 0 |
| 30 Jun 23 | 976 | -268 | 177 | 0 |
| 31 Mar 23 | 988 | -261 | 173 | 0 |
| 31 Dec 22 | 1,004 | -234 | 166 | 0 |
| 30 Sep 22 | 993 | 121 | 163 | 0 |
| 30 Jun 22 | 971 | 123 | 158 | 0 |
| 31 Mar 22 | 956 | 135 | 152 | 0 |
| 31 Dec 21 | 931 | 115 | 149 | 0 |
| 30 Sep 21 | 907 | 36 | 152 | 0 |
| 30 Jun 21 | 881 | 9 | 150 | 0 |
| 31 Mar 21 | 842 | -26 | 140 | 0 |
| 31 Dec 20 | 818 | -39 | 137 | 0 |
| 30 Sep 20 | 795 | -23 | 119 | 0 |
| 30 Jun 20 | 790 | -28 | 128 | 0 |
| 31 Mar 20 | 772 | -29 | 132 | 0 |
| 31 Dec 19 | 778 | -21 | 132 | 0 |
| 31 Dec 18 | 746 | -6 | 126 | 0 |
Quality Earnings: SHC has a large one-off loss of $84.7M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: SHC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SHC has become profitable over the past 5 years, growing earnings by -9.8% per year.
Accelerating Growth: SHC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SHC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: SHC's Return on Equity (15%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 23:15 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sotera Health Company is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Patrick Donnelly | Citigroup Inc |